Triple

T2033078
Position Surface form Disambiguated ID Type / Status
Subject Parkinson's disease E44560 entity
Predicate hasTreatment P4714 FINISHED
Object levodopa
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
 E229731 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: levodopa | Statement: [Parkinson's disease, hasTreatment, levodopa]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: levodopa
Context triple: [Parkinson's disease, hasTreatment, levodopa]
  • A. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • B. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • C. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • D. memantine
    Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
  • E. fampridine
    Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: levodopa
Triple: [Parkinson's disease, hasTreatment, levodopa]
Generated description
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: levodopa
Target entity description: Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
  • A. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • B. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • C. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • D. memantine
    Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
  • E. fampridine
    Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a889144f2481909932f0746a93023d completed March 4, 2026, 7:33 p.m.
NER Named-entity recognition batch_69abb93255248190bd47a54a7b3c7447 completed March 7, 2026, 5:35 a.m.
NED1 Entity disambiguation (via context triple) batch_69ae1ff03d3c8190adef0224aac989bd completed March 9, 2026, 1:18 a.m.
NEDg Description generation batch_69ae2092c3ac8190b2f1f3e9c980f40a completed March 9, 2026, 1:21 a.m.
NED2 Entity disambiguation (via description) batch_69ae21c757c88190a151e01ee0825d85 completed March 9, 2026, 1:26 a.m.
Created at: March 4, 2026, 7:39 p.m.